DCN Dx will have representatives from their assay development, engineering, clinical research, and manufacturing teams on hand to answer questions and discuss their comprehensive services. This multidisciplinary approach ensures that DCN Dx can support every stage of IVD product development, from concept through to manufacturing, including IVD clinical trials and with particular expertise in point-of-care testing.
Visit booth 30 for a demonstration of the miniDxR customizable lateral flow reader. Designed by DCN Dx for point-of-care testing, the miniDxR offers advanced imaging technology, superior sensitivity and specificity, and robust cybersecurity features. It is customizable for diverse diagnostic applications, providing reliable and accurate results in diverse point-of-care settings.
“We are looking forward to demonstrating the miniDxR at the NextGen Dx Summit,” said Pat Vaughan, Ph.D., COO of DCN Dx. “From its advanced capabilities to its range of customization options, our team designed this reader with the specific needs of point-of-care testing in mind.”
“NextGen Dx provides an excellent platform to demonstrate how our integrated CDMO and clinical research services can accelerate the development and commercialization of innovative diagnostic products,” said Mitzi Rettinger, Chief Revenue Officer of DCN Dx. “We are dedicated to partnering with our clients to ensure the success of their IVD programs.”
